Aarti Surfactants Limited has reappointed its top executive leadership and appointed a new independent director following the approval of shareholders at the 8th Annual General Meeting held on September 29, 2026.

The company confirmed that Mr. Nikhil P. Desai has been reappointed as CEO and Managing Director, while Mr. Santosh M. Kakade continues as Whole-time Director designated as an Executive Director. Both appointments are for a term of 5 years, effective from August 20, 2027. Additionally, Prof. Vandana B. Patravale was appointed as an Independent Director for a 5-year term commencing August 22, 2026.

Leadership Continuity and New Appointments

The reappointments ensure stability in the company's operational and strategic leadership. Mr. Desai, who is also part of the Promoter Group and son of Non-Executive Director Parimal H. Desai, brings over 20 years of experience in IT, project management, and business strategy within the pharmaceutical and chemical sectors. His role is exempt from retirement by rotation.

Mr. Kakade, with more than three decades of experience in plant operations and process development, remains liable to retire by rotation. The appointment of Prof. Patravale introduces significant academic and research expertise to the board. She holds a Ph.D. in Pharmaceutics and serves as a Senior Professor at the Institute of Chemical Technology (ICT), Mumbai.

Director Profiles and Terms

Governance and Compliance Details

The appointments were approved pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed that none of the appointed directors are debarred from holding office by SEBI or any other authority. Prof. Patravale is not related to any existing director of the company, ensuring her independence on the board.

This move signals a commitment to long-term governance stability by locking in key management for the next five years while diversifying board expertise with a specialist in pharmaceutics and regulatory affairs.

Aarti Surfactants Limited reported a 30% year-on-year increase in operational revenue to ₹859.13 crore for FY26, driven by strong volume growth and market expansion.

Despite the top-line surge, profitability metrics contracted. EBITDA declined 5% to ₹47.32 crore, causing the operating margin to shrink from 7.56% in FY25 to 5.51% in FY26. The company attributed this margin pressure to input cost volatility, freight fluctuations, and competitive pricing, as detailed in its investor presentation released alongside the 8th Annual General Meeting held on September 29, 2026.

Financial performance highlights

The standalone income statement reveals a divergence between revenue growth and bottom-line performance. While operational revenue rose significantly, total expenses increased at a similar pace, eroding margins. Net profit after tax fell 15% to ₹12.68 crore, with the PAT margin declining from 2.27% to 1.48%.

The board declared a final dividend of ₹1 per equity share, representing a 10% payout on the face value of ₹10. This decision was adopted by shareholders during the meeting, which saw the attendance of 58 members via Video Conferencing.

Business overview and strategic focus

Aarti Surfactants, established through the demerger of Aarti Industries' Home and Personal Care division in 2018, specialises in high-performance ionic, non-ionic, and speciality surfactants. The company serves over 100 customers across more than 50 countries, with a strategic focus on expanding its presence in the high-margin skincare segment.

Key operational metrics disclosed in the presentation include:

• Geographical Split: Domestic sales accounted for 82% of revenue, while international markets contributed 18%.
• Infrastructure: Operations are supported by two manufacturing units in Madhya Pradesh and Silvassa, along with a dedicated R&D centre in Navi Mumbai.
• Workforce: The company employs over 350 people and offers a portfolio of 50+ products.

CEO and Managing Director Nikhil Desai highlighted that the company navigated challenges by focusing on operational efficiencies and capacity utilisation. The presentation noted a 14% CAGR in sales achieved over the six years up to FY24, underscoring long-term growth momentum despite recent margin pressures.

Governance and resolutions

Shareholders approved several ordinary and special business items during the meeting. Key resolutions included:

• Adoption of standalone and consolidated financial statements for FY26.
• Declaration of a dividend of ₹1 per equity share.
• Re-appointment of Dattatray S. Galpalli as director retiring by rotation.
• Re-appointment of Nikhil P. Desai as CEO and Managing Director.
• Re-appointment of Santosh M. Kakade as Whole-time Director.
• Appointment of Vandana B. Patravale as Independent Director.
• Enhancement of borrowing limits and creation of charges on properties.

Chairman Mulesh Savla noted that the Statutory Auditors' Report and the Secretarial Audit Report for FY26 contained no qualifications, reservations, or adverse remarks. The voting process was overseen by Parikh & Associates, who were appointed as Scrutinizers.

What the numbers show

The FY26 results present a classic case of revenue-led growth masking margin erosion. While revenue expanded by 30%, EBITDA contracted by 5%, indicating that incremental sales came at a lower contribution margin or were offset by rising variable costs. The decline in ROCE from 11.54% to 9.72% and ROE from 6.61% to 5.27% further signals reduced capital efficiency.

However, the credit rating agency Crisil upgraded the company's long-term bank facilities rating to 'Crisil A-/Stable' from 'CARE BBB+/Stable' in September 2026. This upgrade suggests that despite the short-term margin dip, lenders view the company's liquidity profile and business risk as stable, likely supported by the robust top-line growth and diversified customer base.